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The cost of schizophrenia and other psychotic disorders is high. Not only do patients pay by the 
disease burden they experience in daily life, their lives are cut short by more than ten years compared 
to the unaffected population. Increased mortality risk may only be ascribed to suicide for a small part; 
the better part is due to less access to health care, lifestyle factors and possible iatrogenic effects of 
treatment, e.g. metabolic syndrome due to second generation antipsychotic medication (Laursen et 
al., 2013; Saha et al., 2007; van Os and Kapur, 2009). The economic cost for society is accordingly high 
(Kennedy et al., 2014). 
Despite these grim statistics, schizophrenia is not necessarily the debilitating and deteriorating 
disease it was once thought to be. Prospective studies show that outcome varies greatly a year after 
diagnosis. Roughly a third of patients show good outcome, another third has poor outcome, with the 
remaining patients at an intermediate level (van Os and Kapur, 2009). Treatment generally constitutes 
the prescription of antipsychotic medication combined with application of supportive interventions 
in the patient’s psychological and social context. Generally speaking, pharmacological treatment is 
still a one-trick pony, i.e. dopamine receptor antagonism. With advancing insights into etiological 
mechanisms, new treatment strategies will develop and outcome stands to improve with personal 
gain for patients, as well as their families, and society as a whole. 
Optimistically, these developments may also alter the perception of psychotic disorder and mental 
illness by the general public. Individuals with psychotic disorder or any other mental illness are not 
to be feared or avoided. It should be understood that they are people struggling with a medical 
condition no different from a patient with a physical diagnosis.
Insight in etiological mechanisms in psychotic disorder can be gained by investigating 
endophenotypes. The studies included in this thesis aimed to examine and differentiate between 
potential peripheral biological endophenotypes and patient-specific characteristics, in relation to 
structural cerebral measures. Although no endophenotypes were identified, the patient-specific 
findings described in this thesis can certainly benefit individuals with psychotic disorder. 
Our work has provided new evidence for the estrogen hypothesis of schizophrenia with support 
for both of its aspects, i.e. estrogen deficiency due to gonadal dysfunction and estrogen-mediated 
neuroprotection providing a relative defense against psychotic disorder. BMD was found to be reduced 
in female patients and is possibly indicative of estrogen deficiency. Higher cumulative exposure to 
estrogen was associated with increased cerebral cortical thickness in women with psychotic disorder. 
The longitudinal data provided no evidence of continuous low estrogen levels (reflected by excessive 
loss of bone mass) in psychotic disorder.
132 |  Chapter 10
Our studies provide a theoretical basis to explain the efficacy of augmentation of estrogen and 
selective estrogen receptor modulators (SERMs) to antipsychotic treatment. To date, clinical trials were 
performed on the premises of epidemiological sex differences while studies with a primary biological 
perspective were lacking.
Reduced BMD due to secondary disease factors (such as lifestyle and iatrogenic effects of PRL-
raising AP) deserves to be recognized as an important issue. Awareness of increased prevalence of 
osteoporosis and fracture risk is warranted in the comprehensive treatment of all health concerns in 
patients with psychotic disorder. 
Serum S100B has been heralded as a promising candidate marker in psychotic disorder. However, in 
our studies, serum S100B was not elevated in individuals with (increased risk of ) psychotic disorder 
in two large independent samples. Nor did we find proof of the validity of S100B as a proxy marker 
for grey and white matter status in healthy individuals or patients with psychotic disorder. From the 
literature, it appears that S100B is possibly too sensitive and too indiscriminate to be useful. S100B 
elevation is perhaps merely indicative of mental activity and/or stress as it is has been shown in 
physicians on duty, activity which may indeed be stressful but not quite pathological (Gazzolo et al., 
2010).
In general, it should be remembered that negative findings make important scientific contributions 
and are crucial in marking directions for future research. This will ultimately benefit patients, the file 
drawer effect will not. 
The concept of linking peripheral endophenotypes to cerebral structure (or function) is a potentially 
useful tool for future research. It may be applicable in investigating therapeutic efficacy and identifying 
regions of interest in the brain in experimental treatment studies, by acquiring neuroimaging data 
pre- and post-intervention.
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